本文關鍵詞：TRAIL及其受體TRAIL-R2與TRAIL-R4在人非小細胞肺癌中表達及其臨床意義　出處：《山西醫(yī)科大學》2015年碩士論文　論文類型：學位論文

  更多相關文章： 非小細胞肺癌 TRAIL TRAIL-R2 TRAIL-R4

【摘要】：目的:研究腫瘤壞死因子相關凋亡誘導配體(tumor necerosis factor-related apoptosis-inducing ligand,TRAIL)及其受體TRAIL-R2(DR5)與TRAIL-R4(Dc R2)在非小細胞肺癌(non-small lung cancer,NSCLC)中的表達規(guī)律,分析其與非小細胞肺癌(NSCLC,Non-small Cell Lung Cancer)的病理分型、分化水平、臨床分期的關系,為臨床上早發(fā)現(xiàn),早治療提供實驗室依據,并且初步探討了TRAIL用于臨床的研究。方法:采用酶聯(lián)免疫吸附實驗(enzyme-linked immunosorbent assay,ELISA)檢測79例NSCLC與80例正常人血清TRAIL的表達水平;采用免疫組化法檢測14例NSCLC組織中TRAIL-R2(DR5)與TRAIL-R4(Dc R2)的表達水平。結果:1、TRAIL在NSCLC血清中的表達明顯高于健康人的表達水平(P=0.0030.05),差異具有統(tǒng)計學意義,與NSCLC的臨床分期具有顯著相關性(組間比較P=0.0000.05),隨著分期的增加,TRAIL的表達水平逐漸降低,與病理分化程度明顯相關(P=0.0000.05),NSCLC的分化程度越高,TRAIL的表達水平越高,與性別、年齡、病理分型無明顯相關性。2、14例NSCLC組織中,TRAIL-R2的表達率為13/14(93%),與臨床分期、病理分化具有顯著相關性,Ⅲ期的表達明顯低于Ⅰ期、Ⅱ期的表達(P=0.0240.05),高分化的組織TRAIL-R2(DR5)的表達明顯高于低分化的表達水平(P=0.0020.05),差異具有統(tǒng)計學意義;TRAIL-R4的表達率為13/14(93%),隨著分期的增加,TRAIL-R4(Dc R2)的表達水平升高(P=0.0420.05),高分化組織的TRAIL-R4(Dc R2)的表達顯著低于低分化組織的表達(P=0.0340.05),差異具有統(tǒng)計學意義,TRAIL-R2的表達與TRAIL-R4的表達呈負相關,與病理分型、年齡、性別無顯著相關性。結論:1.正常人與NSCLC中均有TRAIL的表達,NSCLC患者的表達水平略低。TRA的下降可能是導致NSCLC患者處于處于免疫抑制狀態(tài)或者免疫功能下降的狀態(tài)的原因之一,促進了肺癌的發(fā)生發(fā)展。2.TRAIL在NSCLC的表達與臨床分期、病理分化程度有關,與病理分型、年齡、性別無顯著相關性。3.TRAIL-R2、TRAILR4與臨床分期、病理分化程度密切相關。與病理分型、年齡、性別無顯著相關性。可能由于TRAIL-R2與TRAIL-R4在分布的差異性,導致了腫瘤逃避免疫監(jiān)視,在肺癌的發(fā)生發(fā)展過程中起到了很重要的作用。4.TRAIL-R2與TRAIL-R4的表達呈負相關�？赡芘c二者的分布及作用于信號傳導途徑協(xié)同抑制腫瘤凋亡有關。有助于動態(tài)監(jiān)測肺癌患者病情,但仍需要進一步的研究證實。5.TRAIL-R2的表達為非小細胞肺癌臨床治療提供了靶點,TRAIL-R4在TRAIL誘導非小細胞肺癌細胞凋亡發(fā)揮調節(jié)作用。
[Abstract]:Objective: To study the tumor necrosis factor related apoptosis inducing ligand (tumor necerosis factor-related apoptosis-inducing ligand, TRAIL TRAIL-R2) and its receptor (DR5) and TRAIL-R4 (Dc R2) in non-small cell lung cancer (non-small lung, cancer, NSCLC) in the analysis of the expression pattern, and non-small cell lung cancer (NSCLC, Non-small Cell Lung Cancer). Pathological type, differentiation and clinical stage, early clinical findings, early treatment and provide laboratory evidence, and discuss the TRAIL for clinical research. Methods: using enzyme-linked immunosorbent assay (enzyme-linked immunosorbent, assay, ELISA) to detect the expression of NSCLC in 79 cases and 80 cases of normal human serum TRAIL; TRAIL-R2 was detected by immunohistochemical method in 14 cases of NSCLC tissues (DR5) and TRAIL-R4 (Dc R2) expression level. Results: the expression of TRAIL in 1, NSCLC in the serum was significantly higher than that of healthy people Level (P=0.0030.05), the difference was statistically significant, and NSCLC was significantly correlated with clinical stage (P=0.0000.05 group), with the increase of stage, the expression level of TRAIL decreased gradually and significantly correlated with the degree of pathological differentiation (P=0.0000.05), the higher the degree of NSCLC, the expression level of TRAIL is higher, and gender the age, pathological type, there was no correlation between.2,14 cases of NSCLC tissues, the expression rate of TRAIL-R2 was 13/14 (93%), and clinical stage, pathological differentiation has a significant correlation, the expression of stage III was significantly lower than that in stage I, the expression of phase II (P=0.0240.05), highly differentiated tissue TRAIL-R2 (DR5) was significantly higher than that in the expression level of low differentiation (P=0.0020.05), the difference was statistically significant; the expression rate of TRAIL-R4 was 13/14 (93%), with the increase of stage TRAIL-R4 (Dc R2) increased the expression level (P=0.0420.05), high TRAIL-R4 (Dc R2 organization) The expression was significantly lower than the expression in low differentiation tissues (P=0.0340.05), the difference was statistically significant, TRAIL-R4 had negative correlation with TRAIL-R2, and the pathological type, age, no significant correlation between gender. Conclusion: the expression of TRAIL was 1. in normal and NSCLC, decrease the expression level of NSCLC in patients with lower.TRA may be the cause of NSCLC patients in one of the reasons in immunosuppressed or decreased immune function status, promote the development of.2.TRAIL in lung cancer NSCLC expression and clinical stage, pathological differentiation, and pathological type, age, gender, no significant correlation between.3.TRAIL-R2, TRAILR4 and clinical stage, closely related to pathological differentiation. With the pathological type, age and gender. There is no significant correlation between TRAIL-R2 and TRAIL-R4 may be due to differences in distribution, leads to tumor escape immune surveillance, occurred in lung cancer In the process of development has played a very important role in.4.TRAIL-R2 expression of TRAIL-R4 and the negative correlation. The distribution and effect may be related to the two in the signal transduction pathway of apoptosis. Tumor inhibition contributes to the dynamic monitoring of lung cancer patients, but still need further study to confirm the expression of.5.TRAIL-R2 provides a target for the clinical treatment of non small cell lung cancer, TRAIL-R4 in TRAIL induced non small cell lung cancer cell apoptosis play a regulatory role.

【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R734.2

【相似文獻】

相關期刊論文 前1條

1 吳萍;王家鈺;張旭東;朱孝峰;張林杰;;衣霉素通過上調TRAIL-R2增加胃癌細胞對TRAIL的敏感性[J];腫瘤;2013年01期

相關碩士學位論文 前2條

1 李海燕;TRAIL及其受體TRAIL-R2與TRAIL-R4在人非小細胞肺癌中表達及其臨床意義[D];山西醫(yī)科大學;2015年

2 杜紫燕;TRAIL-R2及TRAIL-R3在人非小細胞肺癌中表達的實驗研究[D];蘇州大學;2006年

，

本文編號：1400359